Effective virtual screening strategy focusing on the identification of novel Bruton's tyrosine kinase inhibitors

• Ligand-based pharmacophore model was generated for BTK inhibitors.
• Structure-based pharmacophore model of BTK was developed for the first time.
• The paper first reported a parallel VS method in BTK inhibitor discovery.
• Cascade docking analysis was performed for reducing the false positive molecules.
• Docking results were further validated by molecular dynamics simulation study.

Dysregulation of the B-cell receptor (BCR) signaling pathway plays a vital role in the pathogenesis and development of B-cell malignancies. Bruton's tyrosine kinase (BTK), a key component in the BCR signaling, has been validated as a valuable target for the treatment of B-cell malignancies. In an attempt to find novel and potent BTK inhibitors, both ligand- and structure-based pharmacophore models were generated using Discovery Studio 2.5 and Ligandscout 3.11 with the aim of screening the ChemBridge database. The resulting hits were then subjected to sequential docking experiments using two independent docking programs, CDOCKER and Glide. Molecules displaying high glide scores and H-bond interactions with the key residue Met477 in both of the docking programs were retained. Drug-like criteria including Lipinski's rule of five and ADMET properties filters were employed for further refinement of the retrieved hits. By clustering, eight promising compounds with novel chemical scaffolds were finally selected and the top two ranking compounds were evaluated by molecular dynamics simulation. We believe that these compounds are of great potential in BTK inhibition and will be used for further investigation.

Figure optionsDownload high-quality image (137 K)Download as PowerPoint slide